What are the appropriate desmopressin dosing regimens for central diabetes insipidus, nocturnal enuresis, and mild hemophilia A or type 1 von Willebrand disease, including pediatric dosing and adjustments for impaired renal function?

Desmopressin Dosing Guidelines

Nocturnal Enuresis (Bedwetting)

Start with oral desmopressin 0.2 mg at bedtime, increasing to 0.4 mg if needed, taken at least 1 hour before sleep, with mandatory fluid restriction to ≤200 mL from evening until morning. 1, 2

Dosing Regimen

• Oral tablet: 0.2 mg initially, titrate to 0.4 mg if inadequate response 1, 2
• Oral melt formulation: 120–240 µg, taken 30–60 minutes before bedtime 2
• Intranasal route (strongly discouraged): 10–40 µg nightly (1–4 sprays) only when oral formulations unavailable due to higher hyponatremia risk 2
• Dosing is not weight- or age-based 1, 2
• Maximum renal concentrating effect occurs 1–2 hours after administration 1, 2

Critical Safety Requirements

• Absolute fluid restriction: ≤200 mL (6 ounces) from evening dose until morning to prevent water intoxication 1, 2, 3
• Polydipsia is an absolute contraindication 1, 2
• Avoid intranasal formulations due to significantly higher risk of hyponatremia and seizures 1, 2
• Perform baseline urine dipstick to rule out glycosuria/proteinuria 1, 2
• Obtain 2-day frequency-volume chart before initiating therapy 1, 2

Expected Outcomes

• Approximately 30% achieve complete dryness (full response) 1, 2
• 40% achieve partial response (significant reduction in wet nights) 1, 2
• Effect is immediate, allowing rapid assessment of efficacy 1

Monitoring and Duration

• Institute regular short drug holidays to assess ongoing need 1, 2
• Monitor serum electrolytes during intercurrent illness 2
• If standard therapy fails with evidence of detrusor overactivity, add anticholinergics (tolterodine, oxybutynin, or propiverine) with 40% response rate 1
• For desmopressin-resistant nocturnal polyuria, consider morning furosemide 0.5 mg/kg plus desmopressin 1

---

Central Diabetes Insipidus

Desmopressin is the treatment of choice for central diabetes insipidus, administered either intranasally or parenterally with individualized dosing based on clinical response. 4

Dosing Considerations

• Dosing must be titrated to clinical response and urine output 4
• Multiple formulations available (intranasal, oral, parenteral) with different bioavailability profiles 5
• Close monitoring required when switching between formulations due to inter-subject variability 5

---

Mild Hemophilia A and Type 1 von Willebrand Disease

Administer desmopressin 0.3 µg/kg intravenously, diluted in 50 mL saline and infused over 30 minutes, as first-line therapy for mild hemophilia A (factor VIII >5%) or von Willebrand disease. 2, 3

Mechanism and Efficacy

• Promotes release of von Willebrand factor and factor VIII from endothelial storage sites 3
• Can increase vWF levels up to fourfold 6
• Facilitates platelet-vessel wall adhesion for hemostatic effect 6
• Transiently increases deficient factor concentrations to levels allowing minor surgery 4

Clinical Applications

• Minor surgical procedures and postoperative hemostasis 3
• Dental extractions, epistaxis, menstrual bleeding 6
• Uremic bleeding 6
• Not recommended for routine use in bleeding trauma patients without specific indication 2
• Meta-analyses show no increased thromboembolic risk 2

---

Renal Impairment Adjustments

Desmopressin is contraindicated in severe renal impairment (creatinine clearance <30 mL/min); close monitoring required when renal function is reduced. 2

• Not recommended for isolated liver disease unless end-stage renal disease also present 2

---

Pediatric Considerations

Age and Weight-Based Dosing Proposals

• Standard flat-dose regimens may be insufficient for entire pediatric population 7
• Recent proposals suggest age- and weight-based dosing regimens, though pediatric data remains limited 5, 7
• Lyophilizate is preferred formulation in children 7
• Bioequivalence established in adults (200 µg tablet = 120 µg lyophilizate) cannot be readily extrapolated to children 7

Pediatric-Specific Pharmacology

• Profound food effect on oral bioavailability demonstrated 7
• Different plasma concentration-time profiles (double absorption peak) observed in children versus adults with lyophilizate formulation 7

---

Critical Safety Warnings and Pitfalls

Hyponatremia Risk Factors

• Extremes of age 5
• Existing comorbidities 5
• Drug interactions 5
• Intranasal formulations 5
• Intercurrent illness 5

Common Prescribing Errors to Avoid

• Never use intranasal formulations for enuresis due to heightened hyponatremia and seizure risk 2
• Never omit fluid restriction counseling—inadequate restriction is the leading cause of water intoxication 2
• Never continue indefinitely without drug holidays—prevents assessment of ongoing necessity 2
• Never prescribe to patients with polydipsia—this is an absolute contraindication 2
• Never expect cure in enuresis—desmopressin provides symptom control with low curative potential 1

Severe Adverse Events

• Water intoxication with hyponatremia and convulsions can occur with inadequate fluid restriction 1, 3
• Central pontine myelinolysis reported with severe hyponatremia, even when sodium corrected at recommended rates 8
• Progressive symptoms include fatigue, anorexia, dizziness, weakness, decreased concentration, falls, and altered mental status 8